BeStock  
Stocks › Biotechnology › BLTE

Belite Bio BLTE

US equityMarket cap rank #2018Biotechnology
$127.38 −$23.64 (-15.65%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $127.38 0.00%
Open$129.00
Prev close$151.02
Day range$120.00 – $135.07
Volume1.04M
Market cap$5.17B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±3.7%last 15 reports
Closed higher10 of 1567% of the time
Best reaction+8.9%
Worst reaction-9.9%

Stock move on the day after each report

-2.6%2023/Q4+1.1%2024/Q1+3.7%2024/Q2+1.3%2024/Q3+0.8%2024/Q4+8.9%2025/Q1+4.6%2025/Q2-9.9%2025/Q3-5.5%2025/Q4+0.6%2026/Q1-2.1%2026/Q2-3.3%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q312 Nov 2026None±8.0%-3.30%Within range
2026/Q213 Aug 2026After Market–-2.09%–
2026/Q120 May 2026None–+0.62%–
2025/Q42 Mar 2026After Market–-5.46%–
2025/Q310 Nov 2025After Market–-9.87%–
2025/Q211 Aug 2025After Market–+4.65%–
2025/Q114 May 2025After Market–+8.88%–
2024/Q417 Mar 2025After Market–+0.84%–
2024/Q312 Nov 2024After Market–+1.33%–
2024/Q212 Aug 2024After Market–+3.73%–
2024/Q114 May 2024After Market–+1.07%–
2023/Q412 Mar 2024After Market–-2.61%–
2023/Q29 Aug 2023After Market–+6.24%–
2022/Q431 Mar 2023None–+1.36%–
2022/Q210 Aug 2022None–+3.54%–

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$36.91M-60.4% YoY
Net profit-$30.27M-39.6% YoY
Diluted EPS-$0.75-15.4% YoY
Free cash flow-$10.56M-129.3% YoY
Operating cash flow-$10.39M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-10.1MDec '24$-14.3MMar '25$-16.3MJun '25$-21.7MSep '25$-25.3MDec '25$-26.9MMar '26$-28.4MJun '26$-30.3MSep '26

Profitability & balance sheet

Return on equity-21.2%
Return on assets-20.7%
Return on invested capital-21.2%
Liabilities / assets2.4%

Discussion

No comments yet — be the first to weigh in on BLTE.

Sign in to join the discussion.

Scroll to Top